Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24802827 | 0.94 | CYP2D6 (0.55) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL17608888 | 0.92 | CYP2D6 (0.61) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL19320649 | 0.90 | MC4R (0.53) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL10205914 | 0.86 | CYP2D6 (0.61) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL14016361 | 0.86 | CYP2D6 (0.58) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL1557055 | 0.84 | CYP2D6 (0.53) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL30155309 | 0.84 | SIGMAR1 (0.46) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL3399535 | 0.84 | ALDH1A1 (0.49) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL25291191 | 0.80 | CYP2D6 (0.51) | SIGMAR1CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL3134881 | 0.80 | SIGMAR1 (0.56) | SIGMAR1CYP2D6TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943893-B | Synthesis method of 4, 7-diazaspiro [2,5] octane compound | 南京爱德程医药科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2024154148-A1 | PROCESS FOR PREPARATION OF RISDIPLAM, NOVEL INTERMEDIATES, AND PROCESS FOR PREPARATION THEREOF | HARMAN FINOCHEM LIMITED (IN) | 2024-07-25 | — | — | WO | claimed |
| CN-111943893-B | Synthesis method of 4, 7-diazaspiro [2,5] octane compound | 南京爱德程医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-111943893-B | Synthesis method of 4, 7-diazaspiro [2,5] octane compound | 南京爱德程医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024154148-A1 | PROCESS FOR PREPARATION OF RISDIPLAM, NOVEL INTERMEDIATES, AND PROCESS FOR PREPARATION THEREOF | HARMAN FINOCHEM LIMITED (IN) | 2024-07-25 | — | — | WO | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2380892-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010082612-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2010044401-A1 | MORPHOLINOPURINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | SIGMAR1 4873/4885CYP2D6 2965/4885TSHR 3953/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | SIGMAR1 2357/4885CYP2D6 2625/4885TSHR 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.